Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | Enzastaurin |
| Trade Name | |
| Synonyms | LY317615|LY-317615 |
| Drug Descriptions |
Enzastaurin (LY317615) is a selective inhibitor PKC-beta, with activity against other PKC isoforms at higher concentrations, which decreases downstream signaling and potentially results in reduced tumor growth (PMID: 16103100, PMID: 17671157, PMID: 22253748, PMID: 32250167). |
| DrugClasses | PKC beta Inhibitor 6 |
| CAS Registry Number | 170364-57-5 |
| NCIT ID | C77392 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| ARV-771 + Enzastaurin | ARV-771 Enzastaurin | 0 | 0 |
| Cyclophosphamide + Doxorubicin + Enzastaurin + Prednisone + Rituximab + Vincristine Sulfate | Cyclophosphamide Doxorubicin Enzastaurin Prednisone Rituximab Vincristine Sulfate | 0 | 0 |
| Enzalutamide + Enzastaurin | Enzalutamide Enzastaurin | 0 | 0 |
| Enzastaurin | Enzastaurin | 0 | 2 |
| Enzastaurin + Temozolomide | Enzastaurin Temozolomide | 0 | 1 |
| Enzastaurin + YK-4-279 | Enzastaurin YK-4-279 | 0 | 0 |